Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556735 | 0.87 | P2RX7 (0.55) | P2RX7EPHX2KMT2AHSD11B1IDO1 | |
| SCHEMBL1675970 | 0.78 | HSD11B1 (0.57) | EPHX2KMT2AHSD11B1FAAH | |
| SCHEMBL16530082 | 0.78 | HSD11B1 (0.57) | EPHX2KMT2AHSD11B1FAAH | |
| SCHEMBL3773962 | 0.75 | NPC1 (0.54) | P2RX7EPHX2KMT2AHSD11B1FAAH | |
| SCHEMBL19808369 | 0.74 | EPHX2 (0.41) | P2RX7EPHX2KMT2AHSD11B1HSD11B2 | |
| SCHEMBL1675682 | 0.74 | KMT2A (0.74) | EPHX2KMT2AHSD11B1FAAH | |
| SCHEMBL3773939 | 0.73 | HSD11B1 (0.45) | P2RX7KMT2AHSD11B1FAAHIDH1 | |
| SCHEMBL13018717 | 0.72 | HSD11B1 (0.44) | P2RX7HSD11B1HSD11B2 | |
| SCHEMBL1761711 | 0.71 | KMT2A (0.54) | EPHX2KMT2AFAAHHDAC6 | |
| SCHEMBL19808221 | 0.69 | EPHX2 (0.38) | P2RX7EPHX2KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | P2RX7 2319/4885EPHX2 1124/4885KMT2A 667/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | P2RX7 2319/4885EPHX2 1124/4885KMT2A 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.